Avisi Technologies presented positive 12-month clinical results for its VisiPlate aqueous shunt at the 2025 American Academy of Ophthalmology (AAO) annual meeting. The data were drawn from the VITA trial, a prospective pilot study evaluating the safety and efficacy of the device in patients with open-angle glaucoma (OAG) who had not previously undergone filtration surgery. The study was conducted at 3 centers in South Africa by 3 implanting surgeons and treated 15 patients with unilateral ab externo implantation.

Baseline mean diurnal intraocular pressure (IOP) was 24.1±6.2 mmHg, with patients using an average of 2.0±1.5 glaucoma medications. At 12 months, mean diurnal IOP decreased to 13.1±2.6 mmHg, representing a 42.6% reduction from baseline, with 46.7% of subjects off glaucoma medications entirely. No serious adverse events were reported, and no patient experienced persistent vision loss.

The VisiPlate is made from an alumina plate coated with parylene-C, a polymer that has been used in other medical implants. It is 5 mm wide and 9 mm long, with 1 mm of the device in the anterior chamber and the rest residing in the subconjunctival space. At just 5 µm thick, it has a very low profile, which creates a bleb that is more aesthetically pleasing and potentially reduces biomechanical stress and risk of conjunctival erosion. GP